Omeros Corp (OMER) Stock Analysis and Metrics

Omeros

NASDAQ: OMER

$9.78 ▼ -0.50 (-4.86%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap707.67 Mn

P/E327.02

P/S26.22

Div. Yield0.00

ROIC (Qtr)-0.07

Total Debt (Qtr)52.81 Mn

Add ratio to table…

About

Omeros Corporation is an innovative commercial stage biotechnology company that discovers and develops first in class protein and small molecule therapeutics for large market and orphan indications. The company concentrates its research on complement mediated diseases, cancers, and addictive or compulsive disorders. Its approved product YARTEMLEA (narsoplimab-wuug) is the first and only therapy for hematopoietic stem cell transplant associated TA TMA, acting as a selective inhibitor of mannose binding lectin associated serine protease 2. Beyond YARTEMLEA, Omeros maintains a deep pipeline that includes product candidates such as Narsoplimab for acute respiratory distress syndrome, OMS1029 a long acting MASP 2 antibody, OMS527 a PDE7 inhibitor for cocaine use disorder and levodopa induced dyskinesia, preclinical programs in MASP 2 and MASP 3 small molecule inhibitors, OncotoX AML for acute myeloid leukemia, and the T CAT platform targeting multidrug resistant organisms. The company operates worldwide research and development activities, retains global commercial rights to YARTEMLEA, and leverages a proprietary intellectual property portfolio with patents extending to the mid 2040s.

Revenue is generated principally from product sales of YARTEMLEA in the United States, where commercial distribution began in January 2026. A major source of non-product revenue is the collaboration with Novo Nordisk, which provided an upfront cash payment of $240 million for exclusive global rights to develop and commercialize the Zaltenibart (OMS906) program. Under this agreement Omeros is eligible to receive up to $510 million in development milestone payments and up to $1.3 billion in sales based milestone payments, plus tiered royalties on net sales ranging from the high single digits to the high teens. Additional potential income stems from licensing arrangements, such as the agreement with Daiichi Sankyo that offers up to $33.5 million in milestone payments and low single digit royalties on future PDE7 inhibitor sales. The company also retains rights to its MASP 3 small molecule program and other early stage assets, which could generate future partnership or licensing revenue.

Omeros occupies a leading niche in the complement therapeutics arena as the sole approved treatment for TA TMA, a condition with significant unmet need. While YARTEMLEA faces potential competition from off label use of C5 inhibitors such as Soliris (eculizumab) and Ultomiris (ravulizumab), it differentiates itself by lacking a boxed warning and a REMS requirement and by not requiring pre treatment vaccinations. The broader complement inhibitor market includes agents like Empaveli (pegcetacoplan), Tavneos (avocopan), PiaSky (crovalimab), Voydeya (danicopan), and Fabhalta (iptacopan), against which Omeros emphasizes its lectin pathway focus and proprietary molecule. The company’s pipeline extends its competitive reach into areas such as acute respiratory distress syndrome, cocaine use disorder, leukemia and infectious disease, providing multiple avenues for growth beyond the current product. Omeros's long standing expertise in complement science and its extensive patent estate, with expirations reaching as late as 2046 for certain assets, reinforce its defensible position in the industry.

The company’s customers are primarily hospitals and transplant centers in the United States, where it engages directly with physicians, nurses, pharmacy teams and reimbursement departments to drive adoption of YARTEMLEA. There are approximately 175 stem cell transplant centers nationwide, with the top 80 facilities accounting for roughly eighty percent of transplant procedures, forming the core focus of its commercial efforts. To support access, Omeros offers the YARTEMLEAssist patient support program, which provides assistance to uninsured or under insured individuals undergoing transplant therapy. While the current commercial footprint is domestic, the company is evaluating partnership structures for potential ex US distribution of YARTEMLEA and future approved products.

Investment Thesis

▲ Bull case

The zaltenibart deal with Novo Nordisk provides Omeros with a transformative non-dilutive capital infusion and ongoing working capital that significantly de-risks the company’s near-term financial profile and fuels long-term growth beyond what the market is pricing in. The upfront $240 million payment, coupled with near-term $100 million milestones and potential for up to $2.1 billion in total payments including royalties in the high teens, creates a substantial war chest. Management used a portion of the upfront to extinguish the $67.1 million term loan and the $17.1 million 2026 convertible notes, leaving only $70.8 million in 2029 convertible notes outstanding. This deleveraging, combined with the Transition Services Agreement (TSA) that reimburses Omeros for zaltenibart-related R&D and operational costs, effectively turns the divested asset into a self-funding engine. The TSA ensures that Novo Nordisk covers ongoing expenses tied to zaltenibart’s development across PNH and other indications, allowing Omeros to redirect internal capital toward higher-margin opportunities like YARTEMLEA and its pipeline without dilution. This structural shift — from a cash-burning biotech to a capital-generative entity with near-term milestones and royalty upside — is underappreciated by investors focused solely on YARTEMLEA’s early commercial ramp. The market is underestimating how this deal not only removes financial overhang but also provides a recurring revenue stream via TSA reimbursements and milestone payments that can sustain operations while YARTEMLEA scales, creating a dual-engine growth model that reduces dependency on any single product launch.
YARTEMLEA’s commercial launch is progressing faster and with fewer barriers than anticipated, driven by unprecedented payer receptivity and rapid formulary adoption that signals deep-rooted clinical need and underestimates the speed of market penetration. Despite being only in its first quarter of commercial availability, YARTEMLEA has secured P&T committee approval and formulary placement at 50% of the top 10 U.S. transplant centers, 40% of the top 20, 35% of the top 40, and approximately 30% of the top 80 centers — covering roughly 80% of national allogeneic stem cell transplant volume. Crucially, Nadia Dac emphasized that lack of formal P&T approval has not hindered access, as the drug is being used in centers without approval due to strong clinical demand and medical exception pathways. Third-party payer pre-authorization requests have been approved 100% to date, with published policies already emerging that support label-consistent use, including twice-weekly dosing without restrictions. This payer behavior — rapid policy development and unrestricted access — is highly unusual for a novel specialty product and indicates that payers recognize YARTEMLEA’s value in preventing costly complications like graft failure or mortality from TA-TMA. The absence of boxed warnings, REMS, or vaccination requirements further reduces administrative burden, making adoption easier than competing off-label C5/C3 inhibitors. The field force’s ability to deliver within 24 hours, combined with strong MSL and reimbursement support, is accelerating uptake beyond clinical trial expectations, with early real-world vial usage showing 70% once-weekly and 30% twice-weekly dosing — a split expected to shift toward twice-weekly as education increases. This suggests higher per-patient utilization than modeled, directly supporting revenue upside. The market is underestimating how quickly YARTEMLEA is becoming standard of care in a setting where no approved therapy previously existed, turning what many view as a slow commercial ramp into a rapid standard-setting adoption curve.
Omeros’ pipeline beyond YARTEMLEA and zaltenibart contains multiple high-potential, under-the-radar catalysts that the market is overlooking due to focus on near-term commercial execution, particularly the T-CAT platform and once-quarterly OMS1029 antibody, which could redefine long-term growth trajectories. The T-CAT platform, designed to combat multidrug-resistant organisms (MDROs) without promoting resistance, has demonstrated efficacy in well-established animal models against WHO-priority pathogens, including gram-negative and gram-positive bacteria. With global anti-infective sales at $135 billion annually and over 39 million projected deaths from MDR bacteria over the next 25 years, T-CAT addresses a massive, growing unmet need. Patents have been filed and a publication is imminent, signaling proximity to clinical translation. Meanwhile, OMS1029 — a once-quarterly dosed MASP-2 antibody currently Phase II ready — and its oral small molecule counterpart target chronic indications in nephrology and neurology, areas with significant patient burden and limited therapeutic options. The company’s oncology platform, OncotoX-AML, has shown superior efficacy to standard of care in preclinical models across 90% of AML genotypes, including historically resistant TP53, NPM1, KMT2A, and FLT3 mutations, with a single course achieving up to 99% selective killing of myeloid progenitor cells in nonhuman primates and no safety signals. IND-enabling studies are underway, with a first-in-human trial targeted for late next year. These programs are not being funded by dilutive financing; instead, they are being advanced using the non-dilutive proceeds from the zaltenibart deal and potential TSA reimbursements. The market is failing to assign value to these early-stage but de-risked assets, which have strong mechanistic rationale, IP protection, and clear paths to clinical proof-of-concept. Omeros is not merely a one-product story; it is building a franchise around complement-targeted therapeutics with applications across acute, chronic, and oncology settings — a diversification strategy that could yield multiple near-term inflection points absent from current valuations.

The zaltenibart deal with Novo Nordisk provides Omeros with a transformative non-dilutive capital infusion and ongoing working capital that significantly de-risks the company’s near-term financial profile and fuels long-term growth beyond what the market is pricing in. The upfront $240 million payment, coupled with near-term $100 million milestones and potential for up to $2.1 billion in total payments including royalties in the high teens, creates a substantial war chest. Management used a portion of the upfront to extinguish the $67.1 million term loan and the $17.1 million 2026 convertible notes, leaving only $70.8 million in 2029 convertible notes outstanding. This deleveraging, combined with the Transition Services Agreement (TSA) that reimburses Omeros for zaltenibart-related R&D and operational costs, effectively turns the divested asset into a self-funding engine. The TSA ensures that Novo Nordisk covers ongoing expenses tied to zaltenibart’s development across PNH and other indications, allowing Omeros to redirect internal capital toward higher-margin opportunities like YARTEMLEA and its pipeline without dilution. This structural shift — from a cash-burning biotech to a capital-generative entity with near-term milestones and royalty upside — is underappreciated by investors focused solely on YARTEMLEA’s early commercial ramp. The market is underestimating how this deal not only removes financial overhang but also provides a recurring revenue stream via TSA reimbursements and milestone payments that can sustain operations while YARTEMLEA scales, creating a dual-engine growth model that reduces dependency on any single product launch.
YARTEMLEA’s commercial launch is progressing faster and with fewer barriers than anticipated, driven by unprecedented payer receptivity and rapid formulary adoption that signals deep-rooted clinical need and underestimates the speed of market penetration. Despite being only in its first quarter of commercial availability, YARTEMLEA has secured P&T committee approval and formulary placement at 50% of the top 10 U.S. transplant centers, 40% of the top 20, 35% of the top 40, and approximately 30% of the top 80 centers — covering roughly 80% of national allogeneic stem cell transplant volume. Crucially, Nadia Dac emphasized that lack of formal P&T approval has not hindered access, as the drug is being used in centers without approval due to strong clinical demand and medical exception pathways. Third-party payer pre-authorization requests have been approved 100% to date, with published policies already emerging that support label-consistent use, including twice-weekly dosing without restrictions. This payer behavior — rapid policy development and unrestricted access — is highly unusual for a novel specialty product and indicates that payers recognize YARTEMLEA’s value in preventing costly complications like graft failure or mortality from TA-TMA. The absence of boxed warnings, REMS, or vaccination requirements further reduces administrative burden, making adoption easier than competing off-label C5/C3 inhibitors. The field force’s ability to deliver within 24 hours, combined with strong MSL and reimbursement support, is accelerating uptake beyond clinical trial expectations, with early real-world vial usage showing 70% once-weekly and 30% twice-weekly dosing — a split expected to shift toward twice-weekly as education increases. This suggests higher per-patient utilization than modeled, directly supporting revenue upside. The market is underestimating how quickly YARTEMLEA is becoming standard of care in a setting where no approved therapy previously existed, turning what many view as a slow commercial ramp into a rapid standard-setting adoption curve.
Omeros’ pipeline beyond YARTEMLEA and zaltenibart contains multiple high-potential, under-the-radar catalysts that the market is overlooking due to focus on near-term commercial execution, particularly the T-CAT platform and once-quarterly OMS1029 antibody, which could redefine long-term growth trajectories. The T-CAT platform, designed to combat multidrug-resistant organisms (MDROs) without promoting resistance, has demonstrated efficacy in well-established animal models against WHO-priority pathogens, including gram-negative and gram-positive bacteria. With global anti-infective sales at $135 billion annually and over 39 million projected deaths from MDR bacteria over the next 25 years, T-CAT addresses a massive, growing unmet need. Patents have been filed and a publication is imminent, signaling proximity to clinical translation. Meanwhile, OMS1029 — a once-quarterly dosed MASP-2 antibody currently Phase II ready — and its oral small molecule counterpart target chronic indications in nephrology and neurology, areas with significant patient burden and limited therapeutic options. The company’s oncology platform, OncotoX-AML, has shown superior efficacy to standard of care in preclinical models across 90% of AML genotypes, including historically resistant TP53, NPM1, KMT2A, and FLT3 mutations, with a single course achieving up to 99% selective killing of myeloid progenitor cells in nonhuman primates and no safety signals. IND-enabling studies are underway, with a first-in-human trial targeted for late next year. These programs are not being funded by dilutive financing; instead, they are being advanced using the non-dilutive proceeds from the zaltenibart deal and potential TSA reimbursements. The market is failing to assign value to these early-stage but de-risked assets, which have strong mechanistic rationale, IP protection, and clear paths to clinical proof-of-concept. Omeros is not merely a one-product story; it is building a franchise around complement-targeted therapeutics with applications across acute, chronic, and oncology settings — a diversification strategy that could yield multiple near-term inflection points absent from current valuations.

▼ Bear case

YARTEMLEA’s commercial trajectory faces significant headwinds from limited patient pool size, pricing pressure risks, and uncertain real-world utilization patterns that could undermine revenue expectations, despite early formulary success. While management highlights formulation approvals at top transplant centers, the total addressable market for TA-TMA remains extremely narrow — estimated at only a few hundred to low-thousand patients annually in the U.S., based on incidence rates of severe complications post-stem cell transplant. Even with broad label coverage (adults and pediatric ≥2 years) and 100% payer pre-authorization approval to date, the absolute number of treatable patients is small, limiting scalability. The per-vial price of approximately $36,000, while justified by clinical benefit, invites scrutiny from payers managing specialty drug budgets, especially as utilization data remains early and variable. Although current real-world usage shows 70% once-weekly and 30% twice-weekly dosing, the expectation of a shift toward twice-weekly — driven by physician education — may not materialize as quickly as hoped, particularly if clinicians remain cautious about increased cost per course. Median utilization in trials was 8–10 vials per course; if real-world use trends toward the lower end due to cost concerns or shorter treatment durations, annual revenue per patient could fall significantly below projections. Furthermore, the reliance on hospital outpatient departments for billing and reimbursement introduces complexity — while 80 top centers cover 80% of volume, fragmentation across smaller sites may delay adoption. The absence of formal guidance on YARTEMLEA revenue in Q1 2026, despite strong early uptake, suggests management lacks confidence in near-term predictability. The market may be ignoring the risk that YARTEMLEA becomes a niche, high-cost therapy used only in refractory cases or academic centers, failing to achieve broad penetration due to economic constraints rather than clinical need, especially if off-label C5/C3 inhibitors remain entrenched due to lower acquisition cost despite higher infection risk.
The zaltenibart deal, while financially transformative in the short term, creates long-term strategic risks by divesting Omeros’ most advanced asset and creating dependency on Novo Nordisk’s execution, with milestone receipts and royalties contingent on external factors outside Omeros’ control. Although the upfront $240 million and near-term $100 million milestones provided immediate liquidity, the company retains no commercial or development rights to zaltenibart globally — Novo Nordisk now controls all aspects of its advancement across PNH and other indications. The $410 million in development and approval milestones and up to $1.3 billion in sales and commercial milestones are entirely at Novo’s discretion, tied to clinical trial outcomes, regulatory timelines, and commercial launch success in indications Omeros cannot influence. While Omeros expresses confidence in receiving the near-term $100 million milestone, it cannot specify what triggers it, indicating a lack of transparency and potential vulnerability to delays or reprioritization by Novo. Furthermore, the tiered royalties up to the high teens, while attractive, are subject to Novo’s pricing, discounting, and market access strategies — factors that could suppress net sales and thus royalty income. The Transition Services Agreement (TSA), while reimbursing Omeros for current costs, is a temporary arrangement tied to the transfer of knowledge and materials; once zaltenibart programs are fully transferred, this revenue stream will cease. Omeros’ retained MASP-3 small molecule program, while promising, is earlier-stage and lacks the near-term de-risking of zaltenibart. By exiting its most valuable clinical asset, Omeros has shifted from a balanced pipeline company to one reliant on a single commercial product (YARTEMLEA) and external partners for future upside, increasing strategic concentration risk. The market may be overlooking how this deal, while strengthening the balance sheet, reduces optionality and long-term autonomy, tying a significant portion of future value to a partner’s execution in therapeutic areas Omeros no longer controls.
Omeros’ broader pipeline beyond YARTEMLEA and the zaltenibart deal remains largely preclinical or early clinical, with significant execution risk, uncertain timelines, and limited near-term catalysts that could disappoint investors expecting rapid diversification. While the T-CAT platform shows promise against MDROs, it is still in preclinical stages with no IND filed, relying on animal model data that may not translate to human efficacy. The path to clinical trials requires additional funding, manufacturing scale-up, and regulatory engagement — all of which are uncertain and not currently financed by non-dilutive sources beyond the zaltenibart proceeds, which are finite. OMS1029, the once-quarterly MASP-2 antibody, is described as Phase II ready but has not yet entered clinical trials; advancing it will require substantial investment in toxicology, dosing studies, and trial design for chronic indications like nephrology or neurology, where placebo effects and slow progression complicate readouts. Similarly, the oral small molecule MASP-2 program lacks clarity on potency, selectivity, and preclinical safety profile. OncotoX-AML, despite compelling preclinical data showing up to 99% killing of myeloid progenitor cells, remains in IND-enabling studies with a first-in-human trial targeted only for late next year — meaning no clinical data is expected before 2027 at the earliest. The company’s reliance on grants (e.g., NIDA for OMS527 in cocaine use disorder) for early-stage programs highlights limited internal capacity to fund multiple parallel initiatives. While management speaks of HEOR analyses and future publications, these are value-demonstration tools, not substitutes for clinical proof. The market may be assigning undue value to these exploratory programs based on mechanistic appeal rather than tangible progress, ignoring the high failure rate in transitioning from preclinical to clinical success, especially in complex areas like immunomodulation and anti-infectives where safety and durability are paramount. Without near-term milestones or partnerships on these assets, Omeros risks becoming a one-product company dependent on YARTEMLEA’s narrow market opportunity, with pipeline value largely speculative and not reflected in near-term inflection points.

YARTEMLEA’s commercial trajectory faces significant headwinds from limited patient pool size, pricing pressure risks, and uncertain real-world utilization patterns that could undermine revenue expectations, despite early formulary success. While management highlights formulation approvals at top transplant centers, the total addressable market for TA-TMA remains extremely narrow — estimated at only a few hundred to low-thousand patients annually in the U.S., based on incidence rates of severe complications post-stem cell transplant. Even with broad label coverage (adults and pediatric ≥2 years) and 100% payer pre-authorization approval to date, the absolute number of treatable patients is small, limiting scalability. The per-vial price of approximately $36,000, while justified by clinical benefit, invites scrutiny from payers managing specialty drug budgets, especially as utilization data remains early and variable. Although current real-world usage shows 70% once-weekly and 30% twice-weekly dosing, the expectation of a shift toward twice-weekly — driven by physician education — may not materialize as quickly as hoped, particularly if clinicians remain cautious about increased cost per course. Median utilization in trials was 8–10 vials per course; if real-world use trends toward the lower end due to cost concerns or shorter treatment durations, annual revenue per patient could fall significantly below projections. Furthermore, the reliance on hospital outpatient departments for billing and reimbursement introduces complexity — while 80 top centers cover 80% of volume, fragmentation across smaller sites may delay adoption. The absence of formal guidance on YARTEMLEA revenue in Q1 2026, despite strong early uptake, suggests management lacks confidence in near-term predictability. The market may be ignoring the risk that YARTEMLEA becomes a niche, high-cost therapy used only in refractory cases or academic centers, failing to achieve broad penetration due to economic constraints rather than clinical need, especially if off-label C5/C3 inhibitors remain entrenched due to lower acquisition cost despite higher infection risk.
The zaltenibart deal, while financially transformative in the short term, creates long-term strategic risks by divesting Omeros’ most advanced asset and creating dependency on Novo Nordisk’s execution, with milestone receipts and royalties contingent on external factors outside Omeros’ control. Although the upfront $240 million and near-term $100 million milestones provided immediate liquidity, the company retains no commercial or development rights to zaltenibart globally — Novo Nordisk now controls all aspects of its advancement across PNH and other indications. The $410 million in development and approval milestones and up to $1.3 billion in sales and commercial milestones are entirely at Novo’s discretion, tied to clinical trial outcomes, regulatory timelines, and commercial launch success in indications Omeros cannot influence. While Omeros expresses confidence in receiving the near-term $100 million milestone, it cannot specify what triggers it, indicating a lack of transparency and potential vulnerability to delays or reprioritization by Novo. Furthermore, the tiered royalties up to the high teens, while attractive, are subject to Novo’s pricing, discounting, and market access strategies — factors that could suppress net sales and thus royalty income. The Transition Services Agreement (TSA), while reimbursing Omeros for current costs, is a temporary arrangement tied to the transfer of knowledge and materials; once zaltenibart programs are fully transferred, this revenue stream will cease. Omeros’ retained MASP-3 small molecule program, while promising, is earlier-stage and lacks the near-term de-risking of zaltenibart. By exiting its most valuable clinical asset, Omeros has shifted from a balanced pipeline company to one reliant on a single commercial product (YARTEMLEA) and external partners for future upside, increasing strategic concentration risk. The market may be overlooking how this deal, while strengthening the balance sheet, reduces optionality and long-term autonomy, tying a significant portion of future value to a partner’s execution in therapeutic areas Omeros no longer controls.
Omeros’ broader pipeline beyond YARTEMLEA and the zaltenibart deal remains largely preclinical or early clinical, with significant execution risk, uncertain timelines, and limited near-term catalysts that could disappoint investors expecting rapid diversification. While the T-CAT platform shows promise against MDROs, it is still in preclinical stages with no IND filed, relying on animal model data that may not translate to human efficacy. The path to clinical trials requires additional funding, manufacturing scale-up, and regulatory engagement — all of which are uncertain and not currently financed by non-dilutive sources beyond the zaltenibart proceeds, which are finite. OMS1029, the once-quarterly MASP-2 antibody, is described as Phase II ready but has not yet entered clinical trials; advancing it will require substantial investment in toxicology, dosing studies, and trial design for chronic indications like nephrology or neurology, where placebo effects and slow progression complicate readouts. Similarly, the oral small molecule MASP-2 program lacks clarity on potency, selectivity, and preclinical safety profile. OncotoX-AML, despite compelling preclinical data showing up to 99% killing of myeloid progenitor cells, remains in IND-enabling studies with a first-in-human trial targeted only for late next year — meaning no clinical data is expected before 2027 at the earliest. The company’s reliance on grants (e.g., NIDA for OMS527 in cocaine use disorder) for early-stage programs highlights limited internal capacity to fund multiple parallel initiatives. While management speaks of HEOR analyses and future publications, these are value-demonstration tools, not substitutes for clinical proof. The market may be assigning undue value to these exploratory programs based on mechanistic appeal rather than tangible progress, ignoring the high failure rate in transitioning from preclinical to clinical success, especially in complex areas like immunomodulation and anti-infectives where safety and durability are paramount. Without near-term milestones or partnerships on these assets, Omeros risks becoming a one-product company dependent on YARTEMLEA’s narrow market opportunity, with pipeline value largely speculative and not reflected in near-term inflection points.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Customer Breakdown of Revenue (2014)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Customer Breakdown of Revenue (2014)

Peer Comparison

Create an account

Sign In

Reset Password